Fate Therapeutics (FATE) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to 0.68.
- Fate Therapeutics' Equity Ratio fell 695.89% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 695.89%. This contributed to the annual value of 0.72 for FY2024, which is 62.49% down from last year.
- Per Fate Therapeutics' latest filing, its Equity Ratio stood at 0.68 for Q3 2025, which was down 695.89% from 0.7 recorded in Q2 2025.
- Fate Therapeutics' Equity Ratio's 5-year high stood at 0.76 during Q1 2023, with a 5-year trough of 0.68 in Q3 2025.
- Moreover, its 5-year median value for Equity Ratio was 0.74 (2021), whereas its average is 0.73.
- Per our database at Business Quant, Fate Therapeutics' Equity Ratio surged by 1927.99% in 2021 and then tumbled by 695.89% in 2025.
- Over the past 5 years, Fate Therapeutics' Equity Ratio (Quarter) stood at 0.74 in 2021, then decreased by 6.9% to 0.69 in 2022, then rose by 6.11% to 0.73 in 2023, then fell by 0.62% to 0.72 in 2024, then decreased by 5.83% to 0.68 in 2025.
- Its Equity Ratio was 0.68 in Q3 2025, compared to 0.7 in Q2 2025 and 0.72 in Q1 2025.